Exelixis, Inc. (EXEL)

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis Shares Rising on CABOMETYX Revenue

Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Integrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXEL

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

Exelixis: The FDA Delay Costs Less Than The Market Thinks

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

U.S. FDA extends review of Exelixis' cancer drug

Baird Financial Group Inc. Raises Holdings in Exelixis, Inc. $EXEL

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?